Eric Loumeau - Sep 14, 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
CHIEF LEGAL OFFICER
Signature
/s/ Eric Loumeau
Stock symbol
ANAB
Transactions as of
Sep 14, 2024
Transactions value $
-$422,361
Form type
4
Date filed
9/17/2024, 06:44 PM
Previous filing
Jul 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $0 +6K +126.58% $0.00 10.7K Sep 14, 2024 Direct F1, F2
transaction ANAB Common Stock Sale -$86.4K -2.22K -20.67% $38.93 8.52K Sep 16, 2024 Direct F3
transaction ANAB Common Stock Options Exercise $70.1K +5K +58.69% $14.02 13.5K Sep 16, 2024 Direct
transaction ANAB Common Stock Sale -$261K -6.5K -48.08% $40.13 7.02K Sep 16, 2024 Direct F4
transaction ANAB Common Stock Sale -$145K -3.78K -53.85% $38.41 3.24K Sep 17, 2024 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Restricted Stock Unit Options Exercise $0 -6K -100% $0.00 0 Sep 14, 2024 Common Stock 6K Direct F1, F6
transaction ANAB Employee Stock Option (right to buy) Options Exercise $0 -5K -6.41% $0.00 73K Sep 16, 2024 Common Stock 5K $14.02 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 Includes 1,500 shares acquired under the Employee Stock Purchase Plan as of May 15, 2024.
F3 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated June 10, 2024.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.05 to $38.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F7 The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F8 In addition to the remaining options to purchase 73,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms.